Relay Therapeutics (RLAY) News Today $2.96 -0.14 (-4.52%) Closing price 03/25/2025 04:00 PM EasternExtended Trading$3.01 +0.05 (+1.82%) As of 08:21 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Relay Therapeutics (NASDAQ:RLAY) Shares Down 3.2% - Should You Sell?Relay Therapeutics (NASDAQ:RLAY) Shares Down 3.2% - What's Next?March 20, 2025 | marketbeat.comRelay Therapeutics’ SWOT analysis: promising drug faces stiff competitionMarch 19, 2025 | investing.comRelay Therapeutics (NASDAQ:RLAY) Trading Down 6.7% - Should You Sell?Relay Therapeutics (NASDAQ:RLAY) Shares Down 6.7% - Here's What HappenedMarch 14, 2025 | marketbeat.comRelay Therapeutics’ SWOT analysis: stock poised for growth amid challengesMarch 14, 2025 | investing.comHC Wainwright Reaffirms Buy Rating for Relay Therapeutics (NASDAQ:RLAY)HC Wainwright reiterated a "buy" rating and set a $16.00 target price on shares of Relay Therapeutics in a report on Friday.March 8, 2025 | marketbeat.comCandriam S.C.A. Acquires 636,494 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY)Candriam S.C.A. lifted its holdings in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 58.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,729,199 shares of the compMarch 8, 2025 | marketbeat.comRelay Therapeutics (NASDAQ:RLAY) Hits New 1-Year Low - Should You Sell?Relay Therapeutics (NASDAQ:RLAY) Sets New 52-Week Low - Here's WhyMarch 6, 2025 | marketbeat.comRelay Therapeutics (NASDAQ:RLAY) Shares Down 8.1% - Here's WhyRelay Therapeutics (NASDAQ:RLAY) Trading Down 8.1% - Here's WhyMarch 4, 2025 | marketbeat.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Receives Average Recommendation of "Moderate Buy" from BrokeragesRelay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) has earned an average rating of "Moderate Buy" from the ten brokerages that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating on the comMarch 2, 2025 | marketbeat.comRelay Therapeutics price target lowered to $12 from $21 at Citizens JMPFebruary 28, 2025 | markets.businessinsider.comBank of America Securities Sticks to Their Buy Rating for Relay Therapeutics (RLAY)February 28, 2025 | markets.businessinsider.comRelay Therapeutics (NASDAQ:RLAY) Sets New 1-Year Low Following Analyst DowngradeRelay Therapeutics (NASDAQ:RLAY) Sets New 12-Month Low Following Analyst DowngradeFebruary 28, 2025 | marketbeat.comThe Goldman Sachs Group Cuts Relay Therapeutics (NASDAQ:RLAY) Price Target to $18.00The Goldman Sachs Group lowered their price target on Relay Therapeutics from $20.00 to $18.00 and set a "buy" rating for the company in a report on Thursday.February 28, 2025 | marketbeat.comStifel Nicolaus Cuts Relay Therapeutics (NASDAQ:RLAY) Price Target to $23.00Stifel Nicolaus dropped their price objective on shares of Relay Therapeutics from $27.00 to $23.00 and set a "buy" rating on the stock in a research note on Thursday.February 28, 2025 | marketbeat.comRelay Therapeutics (NASDAQ:RLAY) Announces Earnings Results, Beats Estimates By $0.14 EPSRelay Therapeutics (NASDAQ:RLAY - Get Free Report) announced its earnings results on Wednesday. The company reported ($0.45) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.14.February 27, 2025 | marketbeat.comRelay Therapeutics reports Q4 EPS (45c), consensus (55c)February 27, 2025 | markets.businessinsider.comTD Cowen Sticks to Their Buy Rating for Relay Therapeutics (RLAY)February 27, 2025 | markets.businessinsider.comRelay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate UpdatesFebruary 26, 2025 | globenewswire.comWhat To Expect From Relay Therapeutics Inc (RLAY) Q4 2024 EarningsFebruary 25, 2025 | finance.yahoo.comRelay Therapeutics to Participate in Two Upcoming Investor ConferencesFebruary 24, 2025 | globenewswire.comRelay Therapeutics (RLAY) Projected to Post Quarterly Earnings on ThursdayRelay Therapeutics (NASDAQ:RLAY) will be releasing earnings before the market opens on Thursday, February 27.February 20, 2025 | marketbeat.comRelay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights on February 26, 2025February 19, 2025 | globenewswire.comRelay Therapeutics, Inc. (NASDAQ:RLAY) CEO Sanjiv Patel Sells 75,324 SharesRelay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) CEO Sanjiv Patel sold 75,324 shares of Relay Therapeutics stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $3.70, for a total transaction of $278,698.80. Following the sale, the chief executive officer now directly owns 883,089 shares of the company's stock, valued at approximately $3,267,429.30. This trade represents a 7.86 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.February 14, 2025 | marketbeat.comInsider Selling: Relay Therapeutics, Inc. (NASDAQ:RLAY) CEO Sells 140,182 Shares of StockRelay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) CEO Sanjiv Patel sold 140,182 shares of Relay Therapeutics stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $3.85, for a total value of $539,700.70. Following the completion of the transaction, the chief executive officer now directly owns 625,948 shares of the company's stock, valued at approximately $2,409,899.80. This represents a 18.30 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.February 14, 2025 | marketbeat.comSanjiv Patel Sells 75,324 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) StockFebruary 14, 2025 | insidertrades.comRelay Therapeutics CEO Sanjiv Patel sells $818,399 in stockFebruary 13, 2025 | msn.comRelay Therapeutics (NASDAQ:RLAY) Shares Gap Down - Should You Sell?Relay Therapeutics (NASDAQ:RLAY) Shares Gap Down - Should You Sell?February 11, 2025 | marketbeat.comEquities Analysts Offer Predictions for RLAY Q2 EarningsRelay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) - Research analysts at Leerink Partnrs issued their Q2 2025 earnings per share (EPS) estimates for Relay Therapeutics in a research report issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens expects that the company will post eFebruary 10, 2025 | marketbeat.comRelay Therapeutics (NASDAQ:RLAY) Shares Down 6.6% - What's Next?Relay Therapeutics (NASDAQ:RLAY) Shares Down 6.6% - Here's WhyFebruary 7, 2025 | marketbeat.comAnalysts Set Expectations for RLAY Q1 EarningsRelay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) - Research analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for Relay Therapeutics in a report issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens anticipates that the company will post earninFebruary 7, 2025 | marketbeat.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Given Average Rating of "Moderate Buy" by BrokeragesRelay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the eleven ratings firms that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and ten have issued a buy recommeFebruary 5, 2025 | marketbeat.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Insider Peter Rahmer Sells 17,250 SharesJanuary 31, 2025 | insidertrades.comPeter Rahmer Sells 17,250 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) StockRelay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) insider Peter Rahmer sold 17,250 shares of the business's stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $4.42, for a total transaction of $76,245.00. Following the transaction, the insider now owns 402,431 shares in the company, valued at approximately $1,778,745.02. The trade was a 4.11 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.January 30, 2025 | marketbeat.comRelay Therapeutics, Inc. (NASDAQ:RLAY) CFO Thomas Catinazzo Sells 20,791 SharesRelay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) CFO Thomas Catinazzo sold 20,791 shares of the business's stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $4.42, for a total transaction of $91,896.22. Following the sale, the chief financial officer now directly owns 379,431 shares in the company, valued at $1,677,085.02. The trade was a 5.19 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.January 30, 2025 | marketbeat.comRelay Therapeutics, Inc. (NASDAQ:RLAY) CFO Sells $166,846.68 in StockRelay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) CFO Thomas Catinazzo sold 36,036 shares of the firm's stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $4.63, for a total transaction of $166,846.68. Following the transaction, the chief financial officer now directly owns 263,190 shares in the company, valued at approximately $1,218,569.70. The trade was a 12.04 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.January 30, 2025 | marketbeat.comPositive Outlook for Relay Therapeutics: Buy Rating on Promising RLY-2680 Developments and Market OpportunitiesJanuary 28, 2025 | markets.businessinsider.comRelay Therapeutics CEO Sanjiv Patel sells $1.76 million in stockJanuary 24, 2025 | msn.comRelay Therapeutics (NASDAQ:RLAY) Shares Gap Down After Insider SellingRelay Therapeutics (NASDAQ:RLAY) Shares Gap Down Following Insider SellingJanuary 24, 2025 | marketbeat.comRelay Therapeutics, Inc. (NASDAQ:RLAY) CEO Sanjiv Patel Sells 125,000 SharesJanuary 24, 2025 | insidertrades.comInsider Selling: Relay Therapeutics, Inc. (NASDAQ:RLAY) CEO Sells $600,000.00 in StockRelay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) CEO Sanjiv Patel sold 125,000 shares of the company's stock in a transaction dated Wednesday, January 22nd. The stock was sold at an average price of $4.80, for a total value of $600,000.00. Following the sale, the chief executive officer now owns 324,548 shares in the company, valued at approximately $1,557,830.40. This trade represents a 27.81 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.January 23, 2025 | marketbeat.comRelay Therapeutics (NASDAQ:RLAY) Trading Down 6% - Here's What HappenedRelay Therapeutics (NASDAQ:RLAY) Stock Price Down 6% - Here's WhyJanuary 23, 2025 | marketbeat.comRelay Therapeutics (NASDAQ:RLAY) Trading 6.8% Higher - Here's WhyRelay Therapeutics (NASDAQ:RLAY) Trading Up 6.8% - Here's WhyJanuary 22, 2025 | marketbeat.comRelay Therapeutics (NASDAQ:RLAY) Hits New 52-Week Low - Should You Sell?Relay Therapeutics (NASDAQ:RLAY) Hits New 52-Week Low - What's Next?January 18, 2025 | marketbeat.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Short Interest UpdateRelay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) was the target of a large increase in short interest in the month of December. As of December 31st, there was short interest totalling 14,950,000 shares, an increase of 23.8% from the December 15th total of 12,080,000 shares. Based on an average daily volume of 2,080,000 shares, the days-to-cover ratio is presently 7.2 days.January 17, 2025 | marketbeat.comWe're Keeping An Eye On Relay Therapeutics' (NASDAQ:RLAY) Cash Burn RateJanuary 17, 2025 | finance.yahoo.comRelay Therapeutics' SWOT analysis: stock poised for growth amid fierce competitionJanuary 17, 2025 | msn.comRelay Therapeutics (NASDAQ:RLAY) Stock Price Down 4.8% - Time to Sell?Relay Therapeutics (NASDAQ:RLAY) Trading Down 4.8% - Should You Sell?January 16, 2025 | marketbeat.comRelay Therapeutics (NASDAQ:RLAY) Reaches New 12-Month Low - What's Next?Relay Therapeutics (NASDAQ:RLAY) Hits New 1-Year Low - Here's WhyJanuary 16, 2025 | marketbeat.comRelay Therapeutics: Buy Rating Amid Competitive Advances and Strategic OpportunitiesJanuary 15, 2025 | markets.businessinsider.comRelay Therapeutics (NASDAQ:RLAY) Shares Down 4.8% - Here's WhyRelay Therapeutics (NASDAQ:RLAY) Stock Price Down 4.8% - Time to Sell?January 14, 2025 | marketbeat.com Remove Ads Get Relay Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RLAY and its competitors with MarketBeat's FREE daily newsletter. Email Address RLAY Media Mentions By Week RLAY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RLAY News Sentiment▼0.680.79▲Average Medical News Sentiment RLAY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RLAY Articles This Week▼24▲RLAY Articles Average Week Remove Ads Get Relay Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RLAY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ARQT News TARS News HRMY News TVTX News JANX News IRON News AGIO News APGE News MESO News VERA News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RLAY) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredHere’s Why Tesla Insiders are Dumping SharesTesla has been on a losing streak ever since Elon Musk first visited the White House in early 2025. Our res...Behind the Markets | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Relay Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Relay Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
